Skip to main content

Advertisement

SpringerLink
Log in

Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet’s disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433–0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2017) One year in review 2017: Behçet’s syndrome. Clin Exp Rheumatol

  2. Vitale A, Rigante D, Lopalco G, Selmi C, Galeazzi M, Iannone F, Cantarini L (2016) Interleukin-1 inhibition in Behçet’s disease. Isr Med Assoc J 18:171–176

    PubMed  Google Scholar 

  3. Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M (2017) Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 13:57–65. https://doi.org/10.1080/1744666X.2016.1205486

    Article  CAS  PubMed  Google Scholar 

  4. Valenti S, Gallizzi R, De Vivo D, Romano C (2017) Intestinal Behçet and Crohn’s disease: two sides of the same coin. Pediatr Rheumatol Online J 15:33. https://doi.org/10.1186/s12969-017-0162-4.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Seyahi E (2016) Behçet’s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol 30:279–295. https://doi.org/10.1016/j.berh.2016.08.002

    Article  PubMed  Google Scholar 

  6. Leccese P, Yazici Y, Olivieri I (2017) Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol 29:12–16

    Article  PubMed  Google Scholar 

  7. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76

    Article  Google Scholar 

  8. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380. https://doi.org/10.1016/j.ajo.2004.03.022

    Article  PubMed  Google Scholar 

  9. Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R, Galeazzi M, Tosi GM, Frediani B, Cantarini L (2017) Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study. Intern Emerg Med 12:947–955

    Article  PubMed  Google Scholar 

  10. Fabiani C, Vitale A, Orlando I, Capozzoli M, Fusco F, Rana F, Franceschini R, Sota J, Frediani B, Galeazzi M, Marco Tosi G, Cantarini L (2017) Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy. Isr Med Assoc J 19:478–483

    PubMed  Google Scholar 

  11. Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR (2007) Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263–1267. https://doi.org/10.1007/s10067-006-0484-y

    Article  CAS  PubMed  Google Scholar 

  12. Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Olivieri I, Yazici H, Hatemi G (2016) A systematic literature review on the treatment of major organ involvement of Behçet’s syndrome informing the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 75:800. [Poster presentation]. https://doi.org/10.1136/annrheumdis-2016-eular.5973

    Article  Google Scholar 

  13. Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70. https://doi.org/10.1016/j.semarthrit.2010.09.002

    Article  CAS  PubMed  Google Scholar 

  14. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, Network FB (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74. https://doi.org/10.1016/j.jaut.2015.06.005

    Article  CAS  PubMed  Google Scholar 

  15. Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology 121:1877–1884. https://doi.org/10.1016/j.ophtha.2014.04.042

    Article  PubMed  Google Scholar 

  16. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484. https://doi.org/10.1002/art.21231

    Article  CAS  PubMed  Google Scholar 

  17. Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm:1–6. https://doi.org/10.1080/09273948.2017.1391297

  18. Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Gentileschi S, Capozzoli M, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-310733

  19. Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L (2017) Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183–189. https://doi.org/10.1007/s10067-016-3480-x

    Article  PubMed  Google Scholar 

  20. Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L (2017) Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451–455. https://doi.org/10.1007/s10067-016-3417-4

    Article  PubMed  Google Scholar 

  21. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  22. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD) (2014) The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347. https://doi.org/10.1111/jdv.12107

    Article  Google Scholar 

  23. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105

    CAS  PubMed  Google Scholar 

  24. Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT, Benucci M, Simonini G, Di Sabatino V, Brizi MG, Galeazzi M (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707

    Article  CAS  PubMed  Google Scholar 

  25. Shendi HM, Walsh D, Edgar JD (2012) Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int 32:249–251. https://doi.org/10.1007/s00296-009-1322-8

    Article  PubMed  Google Scholar 

  26. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A (2003) Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 32:312–314

    Article  CAS  PubMed  Google Scholar 

  27. Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM, Sfriso P, Verrecchia E, Tognon S, Bascherini V, Galeazzi M, Punzi L, Cantarini L (2014) Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 13:1220–1229. https://doi.org/10.1016/j.autrev.2014.08.010

    Article  PubMed  Google Scholar 

  28. Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, Franceschini R, Bacherini D, Frediani B, Galeazzi M, Tosi GM, Cantarini L (2017) Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm:1–6. https://doi.org/10.1080/09273948.2017.1351573

  29. Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, Gerardo DS, Iannone F, Frediani B, Galeazzi M, Lapadula G, Rigante D, Cantarini L (2017) Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease. Clin Rheumatol 36:2063–2069. https://doi.org/10.1007/s10067-017-3627-4

    Article  PubMed  Google Scholar 

  30. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785–96.e3. https://doi.org/10.1016/j.ophtha.2013.09.048

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Claudia Fabiani and Antonio Vitale contributed equally to this work.

Authors and Affiliations

  1. Department of Ophthalmology, Humanitas Clinical and Research Center, via Manzoni 56, 20089, Rozzano, Milan, Italy

    Claudia Fabiani

  2. Ophthalmology and Neurosurgery Department, University of Siena, Siena, Italy

    Claudia Fabiani, Rossella Franceschini, Marco Capozzoli & Gian Marco Tosi

  3. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Policlinico “Le Scotte”, viale Bracci 1, 53100, Siena, Italy

    Antonio Vitale, Jurgen Sota, Ida Orlando, Bruno Frediani, Mauro Galeazzi & Luca Cantarini

  4. Institute of Pediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli”, Rome, Italy

    Donato Rigante

  5. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Giacomo Emmi & Gerardo di Scala

  6. Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

    Giuseppe Lopalco & Florenzo Iannone

  7. Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy

    Lorenzo Vannozzi

  8. Department of Ophthalmology and Otolaryngology, University of Bari, Bari, Italy

    Silvana Guerriero

Authors
  1. Claudia Fabiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donato Rigante
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giacomo Emmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Lopalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jurgen Sota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lorenzo Vannozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gerardo di Scala
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Silvana Guerriero
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ida Orlando
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rossella Franceschini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Marco Capozzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bruno Frediani
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mauro Galeazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Florenzo Iannone
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Gian Marco Tosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Luca Cantarini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Claudia Fabiani or Luca Cantarini.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fabiani, C., Vitale, A., Rigante, D. et al. Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab. Clin Rheumatol 37, 1715–1720 (2018). https://doi.org/10.1007/s10067-018-4092-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4092-4

Keywords

Search

Navigation